AnaSCI - Fitness Evolved

Buy Needles and Syringes with NO PRESCRIPTION   Synthetek Muscle Building And Fat Loss Products   Cheap Pure Supplements

©ALL CONTENT OF THIS WEBSITE IS COPYRIGHTED AND CANNOT BE REPRODUCED WITHOUT THE ADMINISTRATORS CONSENT 2003-2019

   
  Synthetek Syntherol  
   
   
   
Largest Selection of Bodybuilding Products   Largest Selection of Bodybuilding Products   Largest Selection of Bodybuilding Products


User CP FAQ Members List Calendar New Posts Quick Links Log Out

AnaSCI Fitness Evolved  AnaSCI Fitness Evolved  AnaSCI Fitness Evolved  AnaSCI Fitness Evolved  AnaSCI Fitness Evolved


        
        
        
        
        

Automatic Translations (Powered by Yandex):
Albanian Belarusian Catalan Czech Danish Dutch English Estonian Finnish French German Greek Hungarian Italian Latvian Lithuanian Macedonian Norwegian Portuguese Russian Slovak Slovenian Spanish Swedish Turkish Ukrainian

Go Back   Anabolic Steroids Discussion and Bodybuilding Forum > Anabolic Science Section > Anabolic Science Forum

Reply
 
LinkBack Thread Tools Display Modes
Trenbolone Study
Old
  (#1)
Super Moderator - RIP
 
thebrick's Avatar
 
Offline
Posts: 2,513
Join Date: Oct 2012
Trenbolone Study - 01-22-2012, 11:59 AM

Tissue selectivity and potential clinical applicati... [Steroids. 2010] - PubMed - NCBI

steroids. 2010 Jun;75(6):377-89. Epub 2010 Feb 4.
Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity.
Yarrow JF, McCoy SC, Borst SE.
Source

Geriatric Research, Education & Clinical Center, VA Medical Center, Gainesville, FL 32608, United States. [email protected]
Abstract

Recently, the development of selective androgen receptor modulators (sarms) has been suggested as a means of combating the deleterious catabolic effects of hypogonadism, especially in skeletal muscle and bone, without inducing the undesirable androgenic effects (e.g., prostate enlargement and polycythemia) associated with testosterone administration. 17beta-Hydroxyestra-4,9,11-trien-3-one (trenbolone; 17beta-TBOH), a synthetic analog of testosterone, may be capable of inducing SARM-like effects as it binds to androgen receptors (ARs) with approximately three times the affinity of testosterone and has been shown to augment skeletal muscle mass and bone growth and reduce adiposity in a variety of mammalian species. In addition to its direct actions through ARs, 17beta-TBOH may also exert anabolic effects by altering the action of endogenous growth factors or inhibiting the action of glucocorticoids. Compared to testosterone, 17beta-TBOH appears to induce less growth in androgen-sensitive organs which highly express the 5alpha reductase enzyme (e.g., prostate tissue and accessory sex organs). The reduced androgenic effects result from the fact that 17beta-TBOH is metabolized to less potent androgens in vivo; while testosterone undergoes tissue-specific biotransformation to more potent steroids, dihydrotestosterone and 17beta-estradiol, via the 5alpha-reductase and aromatase enzymes, respectively. Thus the metabolism of 17beta-TBOH provides a basis for future research evaluating its safety and efficacy as a means of combating muscle and bone wasting conditions, obesity, and/or androgen insensitivity syndromes in humans, similar to that of other sarms which are currently in development.

Published by Elsevier Inc.

PMID:
20138077
[PubMed - indexed for MEDLINE]

------------------------------------------------------

Am J Physiol Endocrinol Metab. 2011 Apr;300(4):E650-60. Epub 2011 Jan 25.
17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate.
Yarrow JF, Conover CF, McCoy SC, Lipinska JA, Santillana CA, Hance JM, Cannady DF, VanPelt TD, Sanchez J, Conrad BP, Pingel JE, Wronski TJ, Borst SE.
Source

VA Medical Center, University of Florida, Gainesville, 32608-1197, USA. [email protected]
Abstract

Selective androgen receptor modulators (sarms) now under development can protect against muscle and bone loss without causing prostate growth or polycythemia. 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone), a potent testosterone analog, may have SARM-like actions because, unlike testosterone, trenbolone does not undergo tissue-specific 5α-reduction to form more potent androgens. We tested the hypothesis that trenbolone-enanthate (TREN) might prevent orchiectomy-induced losses in muscle and bone and visceral fat accumulation without increasing prostate mass or resulting in adverse hemoglobin elevations. Male F344 rats aged 3 mo underwent orchiectomy or remained intact and were administered graded doses of TREN, supraphysiological testosterone-enanthate, or vehicle for 29 days. In both intact and orchiectomized animals, all TREN doses and supraphysiological testosterone-enanthate augmented androgen-sensitive levator ani/bulbocavernosus muscle mass by 35-40% above shams (P ≤ 0.001) and produced a dose-dependent partial protection against orchiectomy-induced total and trabecular bone mineral density losses (P < 0.05) and visceral fat accumulation (P < 0.05). The lowest doses of TREN successfully maintained prostate mass and hemoglobin concentrations at sham levels in both intact and orchiectomized animals, whereas supraphysiological testosterone-enanthate and high-dose TREN elevated prostate mass by 84 and 68%, respectively (P < 0.01). In summary, low-dose administration of the non-5α-reducible androgen TREN maintains prostate mass and hemoglobin concentrations near the level of shams while producing potent myotrophic actions in skeletal muscle and partial protection against orchiectomy-induced bone loss and visceral fat accumulation. Our findings indicate that TREN has advantages over supraphysiological testosterone and supports the need for future preclinical studies examining the viability of TREN as an option for androgen replacement therapy.

PMID:
21266670
[PubMed - indexed for MEDLINE]
   
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are On



All times are GMT -4. The time now is 12:06 PM.



Content Relevant URLs by vBSEO 3.6.0
Copyright © 2003-2019 AnaSCI.org. All rights reserved.